Retatrutide vs Tirzepatide vs Semaglutide: A Research Comparison
The GLP-1 class of peptides is among the most actively researched in current laboratory science. This guide compares three of them — retatrutide, tirzepatide, and semaglutide — by what distinguishes them at the receptor level, and how to confirm the purity of research-grade material.
Important: These are research compounds. This article describes receptor pharmacology studied in laboratory settings. It makes no clinical, weight-loss, or therapeutic claims, and these compounds are for research use only — not for human or animal consumption.
The Core Difference: Receptor Targets
What separates these three peptides in research is how many incretin receptors each one engages.
| Peptide | Receptor Targets | Class |
|---|---|---|
| Semaglutide | GLP-1 | Single agonist |
| Tirzepatide | GLP-1 + GIP | Dual agonist |
| Retatrutide | GLP-1 + GIP + Glucagon | Triple agonist |
- Semaglutide acts on the GLP-1 receptor alone — the most established single-target compound of the three in research literature.
- Tirzepatide is a dual agonist, engaging both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.
- Retatrutide is a triple agonist, adding glucagon-receptor activity to the GLP-1/GIP profile — the newest and most-studied of the three in recent receptor research.
This receptor breadth is the single most important distinction for researchers comparing the three.
Why Researchers Compare Them
In a laboratory context, the value of comparing single, dual, and triple agonists is mechanistic: each added receptor target changes the signaling profile being studied. A model examining GLP-1 signaling alone is a different experiment from one examining combined GLP-1/GIP/glucagon activity. The compounds are tools for isolating those differences.
None of this comparison implies any human outcome — the receptor pharmacology is what’s being studied, in non-human models.
Purity: The Constant Across All Three
Whichever compound a study calls for, the same quality standard applies. GLP-1 research peptides should be:
- 99%+ pure by HPLC, with the method stated.
- Mass-spectrometry confirmed for correct molecular weight and identity.
- Documented with a batch-specific, third-party certificate of analysis.
- Independently verifiable on the testing lab’s own website.
Because these are blind-tested as a group (a common GLP-1 panel covers semaglutide, tirzepatide, and retatrutide together), a credible lab can confirm identity across all three. For how to evaluate these reports, see our guide on reading a peptide certificate of analysis.
Verifying GLP-1 Research Peptides
At PolixLabs, our GLP-RT (retatrutide) and GLP-TZ (tirzepatide) are third-party tested by Janoshik Analytical, with per-batch certificates published and a live verification link for each lot. You can confirm purity, batch, and test date yourself — see our Lab Results page. Every batch is verifiable, not just claimed.
Frequently Asked Questions
What is the difference between retatrutide, tirzepatide, and semaglutide?
They differ by receptor target: semaglutide is a single GLP-1 agonist, tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist. All are research compounds.
What is a triple agonist?
A triple agonist activates three receptors. Retatrutide engages the GLP-1, GIP, and glucagon receptors, making it the broadest-acting of the three in research.
What purity should GLP-1 research peptides be?
99%+ by HPLC with mass-spectrometry identity confirmation, documented in a verifiable third-party COA.
Are these peptides approved for human use?
These are research compounds supplied for laboratory use only. This article makes no clinical or human-use claims.
PolixLabs supplies third-party verified GLP-1 research peptides including GLP-RT (retatrutide) and GLP-TZ (tirzepatide), each with an independent Janoshik COA. For research use only — not for human or animal consumption.